BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 30840323)

  • 1. Treatment Modalities and Survival in Older Adults with Metastatic Colorectal Cancer in Real Life.
    Gouverneur A; Bezin J; Jové J; Bosco-Lévy P; Fourrier-Réglat A; Noize P
    J Am Geriatr Soc; 2019 May; 67(5):913-919. PubMed ID: 30840323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How are elderly patients treated after a diagnosis of metastatic colorectal cancer in real-life practice? A study in a French teaching hospital.
    Gouverneur A; Rouyer M; Grelaud A; Robinson P; Colombani F; Terrebonne E; Smith D; Fourrier-Réglat A; Noize P
    Fundam Clin Pharmacol; 2017 Feb; 31(1):104-109. PubMed ID: 27600062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Use, Safety, and Effectiveness of Targeted Therapies in First-Line Treatment of Metastatic Colorectal Cancer According to Age: The STROMBOLI Cohort Study.
    Gouverneur A; Coutureau J; Jové J; Rouyer M; Grelaud A; Duc S; Gérard S; Smith D; Ravaud A; Droz C; Bernard MA; Lassalle R; Forrier-Réglat A; Noize P;
    Clin Colorectal Cancer; 2019 Mar; 18(1):e150-e162. PubMed ID: 30630730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
    Vijayvergia N; Li T; Wong YN; Hall MJ; Cohen SJ; Dotan E
    Cancer; 2016 Oct; 122(20):3191-3198. PubMed ID: 27379436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic colorectal cancer prior to expanded RAS assessment: evidence from long-term outcome analysis of a real-life cohort within a dedicated colorectal cancer unit.
    Bertero L; Spadi R; Osella-Abate S; Mariani S; Castellano I; Gambella A; Racca P; Morino M; Cassoni P
    World J Surg Oncol; 2020 Apr; 18(1):65. PubMed ID: 32241284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of selected inflammation-based prognostic markers in relapsed or refractory metastatic colorectal cancer patients.
    Song A; Eo W; Lee S
    World J Gastroenterol; 2015 Nov; 21(43):12410-20. PubMed ID: 26604648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer.
    Razenberg LG; Creemers GJ; Beerepoot LV; Vos AH; van de Wouw AJ; Maas HA; Lemmens VE
    Acta Oncol; 2016 Dec; 55(12):1443-1449. PubMed ID: 27585122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-dependent differences in first-line chemotherapy in patients with metastatic colorectal cancer: the DISCO study.
    Lund CM; Vistisen KK; Dehlendorff C; Rønholt F; Johansen JS; Nielsen DL
    Acta Oncol; 2018 Nov; 57(11):1445-1454. PubMed ID: 30375911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial.
    Froelich MF; Heinemann V; Sommer WH; Holch JW; Schoeppe F; Hesse N; Baumann AB; Kunz WG; Reiser MF; Ricke J; D'Anastasi M; Stintzing S; Modest DP; Kazmierczak PM; Hofmann FO
    Eur Radiol; 2018 Dec; 28(12):5284-5292. PubMed ID: 29882070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in survival of metastatic colorectal cancer: are the benefits of clinical trials reproduced in population-based studies?
    Mitry E; Rollot F; Jooste V; Guiu B; Lepage C; Ghiringhelli F; Faivre J; Bouvier AM
    Eur J Cancer; 2013 Sep; 49(13):2919-25. PubMed ID: 23642328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of palliative chemotherapy in metastatic colorectal cancer patients with an ECOG performance status of 3 and 4.
    Crosara Teixeira M; Marques DF; Ferrari AC; Alves MF; Alex AK; Sabbaga J; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2015 Mar; 14(1):52-7. PubMed ID: 25442812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
    Adenis A; de la Fouchardiere C; Paule B; Burtin P; Tougeron D; Wallet J; Dourthe LM; Etienne PL; Mineur L; Clisant S; Phelip JM; Kramar A; Andre T
    BMC Cancer; 2016 Jul; 16():412. PubMed ID: 27389564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review.
    Gouverneur A; Salvo F; Berdaï D; Moore N; Fourrier-Réglat A; Noize P
    J Geriatr Oncol; 2018 Jan; 9(1):15-23. PubMed ID: 28844343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer.
    Obeidat NA; Pradel FG; Zuckerman IH; DeLisle S; Mullins CD
    Am J Geriatr Pharmacother; 2009 Dec; 7(6):343-54. PubMed ID: 20129255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort.
    Rouyer M; François E; Cunha AS; Monnereau A; Noize P; Robinson P; Droz-Perroteau C; Le Monies de Sagazan A; Jové J; Lassalle R; Moore N; Fourrier-Réglat A; Smith D;
    Clin Colorectal Cancer; 2018 Jun; 17(2):129-139. PubMed ID: 29523416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High- versus low-dose leucovorin in the modified FOLFOX6 regimen for first-line treatment of metastatic colorectal cancer.
    Reynolds J; Chamberland-Tremblay A; Herrington JD; Munoz Maldonado Y; Wong L
    J Oncol Pharm Pract; 2017 Apr; 23(3):173-178. PubMed ID: 26786027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
    Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
    Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metastatic colorectal cancer--analysis of treatment modalities and survival now and then].
    Michl M; Holtzem B; Koch J; Moosmann N; Holch J; Hiddemann W; Heinemann V
    Dtsch Med Wochenschr; 2014 Oct; 139(41):2068-72. PubMed ID: 25268205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.